The global Radioligand Therapy (RLT) market is witnessing strong growth momentum, driven by technological innovation, expanding indications, and increasing global access to targeted radiotherapies. Valued at USD 2.36 billion in 2024, the market is projected to rise to USD 3.15 billion in 2025, and advance at a CAGR of 13.2% from 2025 to 2035, reaching an impressive USD 10.91 billion by the end of the period.

RLT: Merging Nuclear Medicine and Precision Oncology

Radioligand therapy represents a revolutionary shift in cancer treatment, combining precision targeting with radioisotope-based therapy. The market’s rapid expansion is fueled by:

• Increased approvals and label expansions of RLT products
• Manufacturing scale-up for critical isotopes such as Lutetium-177 (Lu-177)
• Rising adoption of PSMA and SSTR PET imaging for precise patient selection

However, isotope scarcity—particularly for Lu-177 and Actinium-225 (Ac-225)—poses supply bottlenecks that may limit growth in the near term.

📘 Download the Full Report: Get PDF Brochure

Comprehensive Market Overview

The MarketsandMarkets report provides an in-depth analysis across 420 tables, 62 figures, and 445 pages, offering granular insights into product trends, market segmentation, and regional dynamics.

By Indication: Prostate Cancer Leads Market Growth

In 2024, prostate cancer dominated the global RLT market, reflecting both a high clinical need and the rapid adoption of novel targeted therapies.

Prostate cancer remains one of the most common malignancies among men worldwide, particularly in advanced and metastatic castration-resistant prostate cancer (mCRPC) cases.

Radioligand therapies such as:

• Lutetium-177 vipivotide tetraxetan (Pluvicto), and
• Emerging PSMA-targeted radiopharmaceuticals like [Lu-177]-PNT2002 and 177Lu-PSMA-I&T,

…have demonstrated remarkable efficacy in extending survival and improving quality of life for patients who have exhausted conventional treatment options.

These therapies are reshaping treatment pathways by offering targeted, minimally invasive solutions with fewer systemic side effects.

By End User: Academic & Comprehensive Cancer Centers Take the Lead

The tertiary care academic and comprehensive cancer centers segment held the largest share of the RLT market in 2024.

These centers are at the forefront of innovation, equipped with state-of-the-art diagnostic and therapeutic technologies and multidisciplinary teams of oncologists, nuclear medicine specialists, and researchers.

They are instrumental in:

• Accelerating clinical trials for emerging RLT candidates
• Driving real-world adoption of novel treatments
• Facilitating collaboration between industry and academia

Their contribution ensures that precision radiopharmaceutical therapies move efficiently from research benches to bedside applications, establishing new standards of care worldwide.

Regional Insights: North America Dominates

In 2024, North America accounted for the largest share of the global RLT market, driven by:

• A robust healthcare infrastructure
• Early adoption of innovative oncology therapies
• Presence of leading pharma and biotech companies
• Strong regulatory support for radiopharmaceutical development

North America’s leadership is also strengthened by its growing network of comprehensive cancer centers and clinical trial hubs, where patients gain access to cutting-edge RLT options.

Furthermore, high incidence rates of prostate cancer and neuroendocrine tumors, coupled with strong investment in nuclear medicine research, continue to boost market expansion across the U.S. and Canada.

📄 Request Sample Report: Click Here

Key Market Players Shaping the RLT Landscape

Novartis (Switzerland)

A global leader in radioligand therapy, Novartis has redefined precision oncology through its groundbreaking RLT portfolio. The company’s flagship products include:

• Lutathera (lutetium Lu 177 dotatate) — approved for gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
• Pluvicto (lutetium Lu 177 vipivotide tetraxetan) — approved for mCRPC

By combining diagnostic imaging with therapeutic delivery (theranostics), Novartis enables targeted treatment with superior efficacy and safety. Its continued investment in R&D and manufacturing capacity underscores its leadership in expanding access to radioligand therapy globally.

Bayer (Germany)

Through its acquisition of Algeta in 2014, Bayer secured a strong foothold in the RLT market with Xofigo (radium-223 dichloride) — the first alpha-emitting radiopharmaceutical for treating castration-resistant prostate cancer (CRPC) with bone metastases.

Xofigo marked a major breakthrough by introducing targeted alpha therapy (TAT), which delivers highly localized radiation to bone lesions while minimizing damage to healthy tissue.

Bayer continues to invest in expanding its RLT pipeline, exploring combination therapies and new oncology indications. Its ongoing partnerships and oncology expertise ensure that it remains a key innovator driving the evolution of targeted radiopharmaceuticals.

Other Key Players in the RLT Market

• Curium Pharma (France)
• Eli Lilly & Co. (Point Biopharma) (US)
• AstraZeneca (Fusion Pharmaceuticals Inc.) (UK)
• Progenics (Lantheus) (US)
• Ariceum Therapeutics (Germany)
• Telix Pharmaceuticals (Australia)
• ITM Isotope Technologies Munich SE (Germany)
• Convergent Therapeutics Inc. (US)
• Orano SA (France)
• Actinium Pharmaceuticals Inc. (US)
• Perspective Therapeutics (US)
• Clarity Pharmaceuticals (Australia)
• Radiopharm Theranostics Ltd (Australia)

These companies are advancing the next generation of radioligand and theranostic innovations, focusing on improved isotope production, novel targeting ligands, and expanded applications beyond prostate and neuroendocrine cancers.

The Future of Radioligand Therapy

The coming decade will mark a new era in nuclear oncology, as RLT continues to gain traction as a mainstream treatment option. Advances in isotope manufacturing, PET imaging, and AI-assisted therapy planning will enhance precision, scalability, and clinical adoption.

As global partnerships between pharma, academia, and isotope suppliers strengthen, radioligand therapy is set to become a cornerstone of personalized cancer treatment — offering renewed hope for patients with hard-to-treat malignancies.

Explore the Full Report for In-Depth Insights: Inquire Now